
According to Benzinga Pro data, during Q1, Mersana Therapeutics (NASDAQ:MRSN) posted sales of $2.04 million. Earnings were up 3.52%, but Mersana Therapeutics still reported an overall loss of $47.26 million. In Q4, Mersana Therapeutics brought in $11.00 thousand in sales but lost $48.98 million in earnings.